An IL-4/IL-13 Dual Antagonist Reduces Lung Inflammation, Airway Hyperresponsiveness, and IgE Production in Mice
- 1 July 2013
- journal article
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 49 (1) , 37-46
Abstract
IL-4 and IL-13 comprise promising targets for therapeutic interventions in asthma and other Th2-associated diseases, but agents targeting either IL-4 or IL-13 alone have shown limited efficacy in human clinical studies. Because these cytokines may involve redundant function, dual targeting holds promise for achieving greater efficacy. We describe a bifunctional therapeutic targeting IL-4 and IL-13, developed by a combination of specific binding domains. IL-4–targeted and IL-13–targeted single chain variable fragments were joined in an optimal configuration, using appropriate linker regions on a novel protein scaffold. The bifunctional IL-4/IL-13 antagonist displayed high affinity for both cytokines. It was a potent and efficient neutralizer of both murine IL-4 and murine IL-13 bioactivity in cytokine-responsive Ba/F3 cells, and exhibited a half-life of approximately 4.7 days in mice. In a murine model of ovalbumin-induced ear swelling, the bifunctional molecule blocked both the IL-4/IL-13–dependent early-phase response and the IL-4–dependent late-phase response. In the ovalbumin-induced lung inflammation model, the bifunctional IL-4/IL-13 antagonist reduced the IL-4–dependent rise in serum IgE titers, and reduced IL-13–dependent airway hyperresponsiveness, lung inflammation, mucin gene expression, and serum chitinase responses. Taken together, these findings demonstrate the effective dual blockade of IL-4 and IL-13 with a single agent, which resulted in the modulation of a more extensive range of endpoints than could be achieved by targeting either cytokine alone.Keywords
This publication has 67 references indexed in Scilit:
- A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthmaEuropean Respiratory Journal, 2012
- IL-13 Receptor α1 Differentially Regulates Aeroallergen-Induced Lung ResponsesThe Journal of Immunology, 2011
- Lebrikizumab Treatment in Adults with AsthmaNew England Journal of Medicine, 2011
- Cytokine inhibition in severe asthma: current knowledge and future directionsCurrent Opinion in Pulmonary Medicine, 2011
- On the domain pairing in chimeric antibodiesMolecular Immunology, 2010
- Engineering of stable bispecific antibodies targeting IL-17A and IL-23Protein Engineering, Design and Selection, 2009
- Distinct roles for IL-13 and IL-4 via IL-13 receptor α1 and the type II IL-4 receptor in asthma pathogenesisProceedings of the National Academy of Sciences, 2008
- Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor α1 chainNature Immunology, 2007
- Chitinases and chitinase-like proteins in TH2 inflammation and asthmaJournal of Allergy and Clinical Immunology, 2005
- Engineered antibody fragments and the rise of single domainsNature Biotechnology, 2005